(firstQuint)A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors.

 Dose Escalation (Part 1): To evaluate safety, pharmacokinetics, pharmacodynamics of PLX8394 in adult and pediatric patients with advanced BRAF- mutated tumors, and to identify the recommended Phase 2 Dose.

 Dose Extension (Part 2): To access objective tumor response to PLX8394 treatment in adult and in pediatric patients with advanced BRAF- mutated tumors, to access RECIST, and to access pharmacokinetics, pharmacodynamics, and safety.

.

 A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors@highlight

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX8394.

